Related Experiment Videos
Management of viral hepatitis C
1Prince of Wales Hospital and Chinese University of Hong Kong, Hong Kong. nancyleung@cuhk.edu.hk
Journal of Gastroenterology and Hepatology
|May 10, 2002
Summary
Hepatitis C virus (HCV) treatments improved with combination therapy, increasing sustained response (SR) rates. However, challenges remain regarding adverse events, cost, and treatment for specific patient groups.
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Background:
- Hepatitis C virus (HCV) identified in 1989 causes chronic hepatitis, cirrhosis, and liver cancer.
- Global HCV prevalence is 1-3%, transmitted via blood products, needles, and drug use.
- Interferon (IFN) monotherapy for chronic hepatitis C (CHC) yielded unsatisfactory sustained response (SR) rates (15-20%).
Purpose of the Study:
- To review advances in Hepatitis C virus (HCV) therapy.
- To evaluate the efficacy and limitations of combination therapies for chronic hepatitis C (CHC).
Main Methods:
- Review of Interferon (IFN) and combination therapies for chronic hepatitis C (CHC).
- Analysis of sustained response (SR) rates, patient subgroups, and adverse events.
Main Results:
- IFN-ribavirin combination therapy significantly increased SR to 30-40%.
- Pegylated IFN combined with ribavirin achieved up to 60% SR, benefiting patients with advanced liver disease.
- Adverse events occurred in 23-27% of patients, necessitating treatment discontinuation.
Conclusions:
- Combination therapy represents a major advance in CHC treatment, improving SR rates.
- Unresolved issues include therapy for specific populations (children, elderly, comorbidities) and treatment affordability.
- Further research is needed to address treatment accessibility and optimize outcomes for all HCV patients.